A study of autologous bone marrow transplantation in patients with small cell lung cancer.

DOI Web Site
  • Ieki Ryuji
    Department of Internal Medicine, Institute of Medical Science, University of Tokyo
  • Asano Shigetaka
    Department of Internal Medicine, Institute of Medical Science, University of Tokyo
  • Morisaki Takayuki
    Department of Internal Medicine, Institute of Medical Science, University of Tokyo
  • Kodo Hideki
    Department of Internal Medicine, Institute of Medical Science, University of Tokyo
  • Miwa Shiro
    Department of Internal Medicine, Institute of Medical Science, University of Tokyo
  • IMS Bone Marrow Transplantation Team
    Department of Internal Medicine, Institute of Medical Science, University of Tokyo
  • Hirayama Masakiyo
    Department of Internal Medicine, Tokyo Metropolitan Komagome Hospital
  • Uetake Takeshi
    Department of Internal Medicine, Tokyo Metropolitan Komagome Hospital
  • Kudo Shoji
    Department of Internal Medicine, Tokyo Metropolitan Komagome Hospital
  • Kimura Hitoshi
    Department of Internal Medicine, Tokyo Metropolitan Komagome Hospital
  • Ikeda Takaaki
    Department of Thoracic Surgery, Tokyo Metropolitan Komagome Hospital

Bibliographic Information

Other Title
  • 肺小細胞癌に対する自家骨髄移植療法の検討

Search this article

Description

Five patients with extensive small cell carcinoma of the lung (SCLC) were treated by highdose chemotherapy with autologous bone marrow rescue (Auto-BMT). At the time of Auto-BMT, 2 of five patients were in partial response (PR), and the remaining patients were in a resistant state to conventional chemotherapy.<BR>By Auto-BMT, the two patients in PR status achieved complete remission (CR), and 2 of the three patients in resistant status achieved PR. The other patient was not evaluable because he died of drug-related leukopenia and sepsis.<BR>Survival of the patients showing PR was 1.5 and 6 months after Auto-BMT, while that of one patient in CR was 9.5 months (21.5 months after onset). The cause of death of the above three patients was relapse. However another patient in CR remains alive and disease-free without maintenance chemotherapy for more than 17 months (39 months after onset). This report suggests that Auto-BMT may be useful for patients with extensive SCLC, if they are not in the resistant state.

Journal

  • Haigan

    Haigan 28 (2), 205-212, 1988

    The Japan Lung Cancer Society

Keywords

Details 詳細情報について

Report a problem

Back to top